Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Sold by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. reduced its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 45.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,829 shares of the company’s stock after selling 7,446 shares during the period. E Fund Management Co. Ltd.’s holdings in Dyne Therapeutics were worth $312,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Nisa Investment Advisors LLC lifted its position in Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after purchasing an additional 669 shares during the period. Ameritas Investment Partners Inc. lifted its position in Dyne Therapeutics by 28.0% during the first quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock valued at $167,000 after purchasing an additional 1,291 shares during the period. SG Americas Securities LLC acquired a new position in Dyne Therapeutics during the second quarter valued at $217,000. American Century Companies Inc. acquired a new position in Dyne Therapeutics during the second quarter valued at $228,000. Finally, EntryPoint Capital LLC acquired a new position in Dyne Therapeutics during the first quarter valued at $214,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Dyne Therapeutics

In related news, CEO John Cox bought 32,000 shares of the business’s stock in a transaction dated Wednesday, September 4th. The stock was acquired at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the completion of the purchase, the chief executive officer now directly owns 8,000 shares of the company’s stock, valued at $264,320. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, COO Susanna Gatti High sold 29,787 shares of the company’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $35.01, for a total transaction of $1,042,842.87. Following the completion of the sale, the chief operating officer now owns 148,792 shares of the company’s stock, valued at approximately $5,209,207.92. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO John Cox acquired 32,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The shares were acquired at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the purchase, the chief executive officer now owns 8,000 shares in the company, valued at approximately $264,320. The disclosure for this purchase can be found here. Corporate insiders own 20.77% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on DYN shares. StockNews.com downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday. HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research report on Wednesday, September 4th. Oppenheimer restated an “outperform” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. Morgan Stanley boosted their target price on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Finally, Piper Sandler lifted their price objective on shares of Dyne Therapeutics from $43.00 to $53.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $51.40.

Dyne Therapeutics Stock Down 0.8 %

DYN stock opened at $34.34 on Thursday. The stock has a market capitalization of $3.00 billion, a P/E ratio of -8.65 and a beta of 1.07. The firm has a 50-day simple moving average of $41.38 and a 200-day simple moving average of $33.47. Dyne Therapeutics, Inc. has a 52 week low of $6.40 and a 52 week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Monday, August 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. On average, analysts expect that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.